Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 intravenous C1 esterase inhibitor for acute hereditary angioedema attacks and pre-procedure prevention
2023-503507-29-00Phase 3Authorised
- Sponsor
- Octapharma Pharmazeutika Produktionsgesellschaft mbH
- Start
- Jan 2024
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 14
01
Overview
Phase 3, randomised, double-blind trial of c1-esterase inhibitor in hereditary angioedema (HAE) (3 arms), sponsored by Octapharma Pharmazeutika Produktionsgesellschaft mbH. Planned start Jan 2024; status: authorised.
02
Drugs
c1-esterase inhibitor
03
Conditions
hereditary angioedema (HAE)
Beyond the preview
Go deeper on 2023-503507-29-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-503507-29-00.